ArticleRheumatology and therapy2023

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.

Rieke Alten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.